A new Chinese herbal medicine, CDD-2101, developed in Hong Kong for constipation, has been authorized by the U.S. Food and Drug Administration (FDA) to undergo a clinical trial.
- CDD-2101, also known as MaZiRenWan (MZRW), is a traditional Chinese medicine formula consisting of six herbs
- Its use in the treatment of constipation has been documented for several centuries
- The herbal drug has finally got approval from U.S FDA to evaluate its safety and efficacy
Constipation Treatment: A Review
Go to source).
In such a scenario, a new herbal drug developed in Hong Kong has been authorized to conduct a clinical trial in the US. The Centre for Chinese Herbal Medicine Drug Development (CDD) of Hong Kong Baptist University (HKBU) has developed this new Chinese herbal medicine for treating constipation.
New Chinese Herbal Medicine, CDD-2101, for Constipation
Considering the success of the Investigational New Drug Application sent to the U.S. Food and Drug Administration (FDA), CDD has been approved to conduct a phase I clinical trial of the new drug. The clinical trial will start later this year.Constipation occurs when the muscles of the large intestine do not properly move the food particles through and out of the colon. Slow movement of food can result in excess absorption of water by the colon, causing hard, dry stools.
In general, normal movements should be soft and easy to pass and should happen daily. However, it is common for people to have painful constipation and pass stools only a few times a week, or have less frequent bowel movement.
The reasons behind the imbalance of water in the colon, or the improper functioning of intestinal muscles can be different. Finding the root cause is very different and people often go for temporary relief.
Roles of Chinese Medicine and Gut Microbiota in Chronic Constipation
Go to source).
The formula of MaZiRenWan (MZRW) composed of six Chinese herbs has been commonly used for constipation throughout Asia since 200 A.D. By combining the actions of these herbs, MZRW can moisten the Intestines, drains heat, promotes bowel movement, and unblocks the bowel.
Milestone of Chinese Medicine in International Standards
This new approval move for clinical trials could give us a better picture of the herbal drug. The main ingredients of the drug to be used in the clinical trial, CDD-2101 contain hemp seed, bitter apricot seed, rhubarb, bran stir-fried immature orange fruit, magnolia bark, and white peony root.The HKBU research team collaborated with researchers from the University of Chicago and the University of Macau to submit an Investigational New Drug Application for CDD-2101 according to the requirements for botanical drug development of the U.S. FDA. Later they got the authorization to conduct a phase I clinical trial.
HKBU is exceptional in promoting the development of Chinese medicine and conducting cutting-edge scientific research in this area. The University received funding to establish the CDD in 2020, which significantly increased its comprehensive capabilities in the research and development of Chinese medicine (3✔ ✔Trusted Source
Chinese Herbal Medicine (MaZiRenWan) Improves Bowel Movement in Functional Constipation Through Down-Regulating Oleamide
Go to source).
The clinical trial in the US will provide them with invaluable experience in conducting clinical trials at Hong Kong’s first Chinese Medicine Hospital in the future.
CDD-2101 is a novel drug developed by combining a traditional Chinese herbal formulation and advanced technologies, the U.S. FDA’s authorization to conduct a clinical trial for this drug is considered an important milestone in the development of Chinese medicine and it once again reflects the dedication to promoting the internationalization of Chinese medicine.
The trial will start later this year using 20 healthy participants. The participants will be asked to take a single dose of CDD-2101 or a placebo under 24-hour surveillance in a research center in the US.
The phase I clinical trial will be followed by a phase II study to collect the safety and efficacy data from constipation patients. A large-scale phase III study will further evaluate the treatment efficacy of CDD-2101 and detects any unforeseeable side effects.
After the completion of phase II and III clinical trials, along with animal studies and human clinical trials, the details of the manufacturing of the drug in a New Drug Application will be submitted to the U.S. FDA for review.
References:
- Constipation Treatment: A Review - (https://journals.lww.com/orthopaedicnursing/Abstract/2020/05000/Constipation_Treatment__A_Review.13.aspx)
- Roles of Chinese Medicine and Gut Microbiota in Chronic Constipation - (https://www.hindawi.com/journals/ecam/2019/9372563/)
- Chinese Herbal Medicine (MaZiRenWan) Improves Bowel Movement in Functional Constipation Through Down-Regulating Oleamide - (https://www.frontiersin.org/articles/10.3389/fphar.2019.01570/full)
Source-Medindia